secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193125-24-196961
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Therapeutics Reports Preliminary Q2 2024 Revenue of $4.2-$4.6 Million, Net Loss Widens to $18.9-$19.8 Million
--------------------------------------------------------------------------------

- Revenue for Q2 2024 expected between $4.2M and $4.6M, down from $8.47M in Q2 2023 which included a $5.0M milestone payment from AZSTARYS license.
- Net loss for Q2 2024 estimated at $18.9M to $19.8M, compared to a $2.6M net loss in the prior-year quarter.
- Preliminary diluted net loss per share ranges from ($0.47) to ($0.45), versus ($0.08) in Q2 2023.
- Cash and cash equivalents as of June 30, 2024 were approximately $49.3 million.
- The decrease in revenue is partially offset by reimbursements under AZSTARYS License Agreement and increased French expanded access program reimbursements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000119312524196961/0001193125-24-196961-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000119312524196961/d881941d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-196961

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer